Emerging RAS-directed therapies for cancer

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• RAS oncogenes are frequently mutated in human cancers, posing a significant disease burden.
• Despite decades of research, effective targeting of RAS mutations has been difficult.
• Advances in understanding RAS isoforms and effector signaling have informed therapeutic strategies.

Purpose of the Study:

• To review diverse historical and current approaches to RAS oncogene inhibition.
• To focus on recent advancements in the direct inhibition of KRAS(G12C) mutations.
• To highlight the therapeutic potential of novel RAS-targeting strategies.

Main Methods:

• Literature review of RAS oncogene research and therapeutic strategies.
• Analysis of recent clinical trial data for direct RAS inhibitors.
• Focus on the structural and functional understanding of KRAS(G12C).

Main Results:

• Inhibition of RAS effector signaling has shown some success.
• Direct RAS inhibition has been achieved in a trial setting.
• KRAS(G12C) is a key target for direct inhibition strategies.

Conclusions:

• Direct RAS inhibition, particularly of KRAS(G12C), represents a promising new frontier in cancer therapy.
• While not yet in widespread clinical practice, these developments offer significant hope for treating RAS-mutant cancers.
• Continued research into RAS inhibition is crucial for advancing cancer treatment.